Genetics
Pharmacogenetics
Panels that support decisions on drug response and metabolism.
Personalized medicine · Genetics · Epigenetics
We create the next generation of genetic and epigenetic products
Multiplex lets you design, develop and deploy custom panels in under three months — from scientific evidence to the final report.
We build, process and sequence the complete kit end to end, at a fraction of the market cost.
A cost per sample up to 4× lower than conventional alternatives.
< 3 months
New panel development
From the clinical question to a validated product.
140+ SNPs
Per genetic panel
High-density multiplexed analysis capacity.
up to 4×
Cheaper per sample
Versus the cost of conventional market alternatives.
End to end
Kit build, processing and sequencing
The whole flow integrated in a single platform.
The platform
A factory for personalized-medicine products
Multiplex turns scientific evidence into new genetic and epigenetic products with clinical and commercial applications. We are not just a lab: we are the technological infrastructure that lets health organizations design, validate and scale their own molecular products.
We design
Genetic and epigenetic panels tailored to each organization's clinical or commercial goal.
We develop
Biomarker selection, analytical validation and bioinformatics, in under three months.
We deploy
Interpretation, custom reports and white-label integration via API.
Capabilities
Genetics available today, epigenetics in development
Our genetics line is already operational. Epigenetics is next, on the same development, processing and interpretation infrastructure.
GeneticsAvailable
High-density SNP panels
Design and analysis of panels with 140+ SNPs for pharmacogenetics, cardiometabolic risk, nutrition and preventive health.
- 140+ SNPs per panel
- Cost per sample up to 4× lower than market
- White-label development
EpigeneticsIn development
Epigenetic panels and monitoring
Our next line. Backed by a solid scientific thesis and our already-installed platform capacity; not yet commercially available.
- Backed by a solid scientific thesis
- Leverages the installed platform capacity
- In development — coming soon
Development process
From the clinical question to a product ready to scale
We control every stage of the molecular product's life cycle. This shortens development time and ensures consistency between the evidence and the final report.
Phase 1
Definition
- 01Goal definition
- 02Evidence review
- 03Biomarker selection
Phase 2
Design and validation
- 04Panel design
- 05Development and validation
Phase 3
Lab and analysis
- 06Sample processing
- 07Bioinformatics
- 08Interpretation
Phase 4
Delivery and integration
- 09Report generation
- 10Clinical or commercial integration
Use cases
One design platform, many possible products
More than a closed catalog, Multiplex is a design platform: we select biomarkers, define the panel architecture and build the interpretation for each goal. That lets us develop genetic panels for a range of clinical and commercial domains. These are some of the use cases it already enables.
Genetics
Personalized nutrition
Variants linked to metabolism and micronutrients for nutrition programs.
Genetics
Cardiometabolic risk
Markers related to metabolic and cardiovascular profiles.
Programs
Preventive health
Molecular information as input for prevention initiatives.
Genetics
Maternal and child health
Panels focused on the maternal-child cycle, with scientific prudence.
Programs
Corporate programs
Wellness and metabolic health for employee populations.
Epigenetics
Epigenetic monitoring
Line in development: assessment before and after interventions at the population level.
White label
White label
Genetic products —and soon epigenetic ones— ready to launch under your brand.
Programs
Applied research
Custom panels and processing for studies and cohorts.
Genetics
LatAm population panels
Panels adapted to the characteristics of Latin American populations.
Own products
Our products are proof of the platform
Mynu and Mynu Baby show how Multiplex turns scientific evidence into finished products, from sample to report.
Mynu
Nutritional genetics and personalized-medicine test
Accessible pricing, up to 4× cheaper than market alternatives.
Mynu Baby
Genetic test for the baby's health and growth
Developed and available: analyzes the baby's genetic predispositions from a buccal swab.
For companies
Your next genetic product, under your own brand
Clinics, laboratories, insurers, pharmacies and wellness companies use Multiplex as their engine for developing white-label molecular products.
- Clinics
- Laboratories
- Insurers
- Pharmacies
- Wellness
- Digital health
Frequently asked questions
The essentials about Multiplex
We are a technology platform for personalized medicine. We design, develop and deploy genetic products end to end —with an epigenetics line in development— and include lab capacity as part of the process.
Our platform capacity allows a new panel to be developed in under three months, from goal definition to a validated product.
By handling kit build, processing and sequencing in house, our cost per sample can be up to 4× lower than conventional market alternatives. The comparison is indicative; the final price of each product depends on its scope, volume and integration.
It is a genetic or epigenetic product developed by Multiplex that your organization launches under its own brand, integrated into your clinical or commercial operation.
The platform is ready to integrate via API, delivering results and custom reports to our clients' platforms, apps or clinical systems.
We treat genetic data as highly sensitive information, with separation of contexts between patients, companies and professionals, and principles of confidentiality and data minimization.
Let's talk about your organization's next personalized-medicine product
Tell us what you want to develop. We design a tailored technical and commercial proposal.